Passani Andrea, Posarelli Chiara, Sframeli Angela Tindara, Perciballi Laura, Pellegrini Marco, Guidi Gianluca, Figus Michele
Ophthalmology, Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, 56126 Pisa, Italy.
Ophthalmology, Head and Neck Department, S.Orsola-Malpighi Teaching Hospital-University of Bologna, 40138 Bologna, Italy.
J Clin Med. 2020 Dec 8;9(12):3978. doi: 10.3390/jcm9123978.
Glaucoma is one of the principal causes of irreversible blindness worldwide. Yet, intraocular pressure (IOP) is the main modifiable risk factor for disease progression. In the never-ending challenge to develop new and effective drugs, several molecules have been tested as anti-glaucoma agents thanks to their pressure-lowering capabilities. Among these molecules, the cannabinoids have been investigated as possible anti-glaucoma drugs since the early 1970s. Cannabinoids are a large class of chemical compounds that exploit their effects by interaction with cannabinoid receptors 1 and 2. These receptors are widely expressed in the human retina where they may influence important functions such as photo-transduction, amacrine cell network maintenance, and IOP regulation. Therefore, in past years several studies have been conducted in order to assess the IOP lowering effects of cannabinoids. PRISMA guidelines have been used to perform a literature search on Pubmed and Scopus aiming to investigate the mechanism of IOP lowering effects and the potential benefits of orally administered, inhaled, topical, and intravenous cannabinoids in the treatment of glaucoma patients.
青光眼是全球不可逆性失明的主要原因之一。然而，眼压（IOP）是疾病进展的主要可改变风险因素。在开发新型有效药物的无尽挑战中，一些分子因其降眼压能力而被作为抗青光眼药物进行测试。在这些分子中，自20世纪70年代初以来，大麻素就被研究作为可能的抗青光眼药物。大麻素是一大类通过与大麻素受体1和2相互作用发挥作用的化合物。这些受体在人类视网膜中广泛表达，可能影响光转导、无长突细胞网络维持和眼压调节等重要功能。因此，在过去几年中进行了多项研究，以评估大麻素的降眼压作用。已使用PRISMA指南在PubMed和Scopus上进行文献检索，旨在研究口服、吸入、局部和静脉注射大麻素降低眼压作用的机制以及在治疗青光眼患者中的潜在益处。
